Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
MYC; Peptide therapeutic; Mini-protein
Beaulieu ME, Soucek L. Finding MYCure. Mol Cell Oncol. 2019 Jun 20;6(5):e1618178.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/5775
The following license files are associated with this item: